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Tetrahydrobiopterin (BH4) is the cofactor for phenyl-
alanine hydroxylase (PAH) and is essential to treat
diﬀerent forms of hyperphenylalaninaemia, i.e. patients
with defects in the biosynthesis of BH4, but also in the
PAH gene [1, 4,5]. Responsiveness of mutant PAH to
BH4 administration relies on a chemical chaperon eﬀect
of BH4 preventing PAH from protein misfolding and
inactivation [6], but several other mechanisms may also
be involved [2]. Recently, we reported that sublingual
administration of BH4 tablets in a single control person
resulted in 58%–67% higher plasma BH4 concentra-
tions than the usual oral route [3]. Drawbacks included
rapid decomposition of tablets, acidic taste, and in-
creased salivation. Since sublingual application could
reduce therapy costs, orange ﬂavoured artiﬁcially
sweetened BH4 pastilles were tested on four healthy
volunteers and a child with mild phenylketonuria
(PKU).
BH4 (Schircks, Switzerland) was administered to
four healthy male volunteers (age 28–57 years) on 2
subsequent days either as tablets (50 mg) or pastilles
(100 mg, containing 5 mg aspartame and orange ar-
oma) with a 1 week wash-out between the two trials.
Blood was collected before, and 1, 2, 3, and 4 h after
administration. An 8-year-old patient with mild PKU
(genotype P281L/R261Q) who was already on regular
BH4 therapy was treated with BH4 pastilles (sublin-
gually, 12 mg/kg/day; bid) in addition to P-AM 2
formula for 2 weeks. Written consensus was obtained
from the family.
In the four healthy male volunteers, total biopterin
values before and up to 4 h after oral and sublingual
administration were compared (Fig. 1A). No statisti-
cally signiﬁcant diﬀerence between oral and sublingual
administration was observed. Pterin concentrations in-
creased after both oral and sublingual administration,
reﬂecting instability of BH4 in blood. The ratio of
pterin to cumulated biopterin and pterin ranged be-
tween 22.8% and 33.5%. Summing biopterin and
pterin instead of total biopterin did not alter the ratio
between oral and sublingual administration (data not
shown).
Changing from standard therapy to sublingual
administration in a child with mild PKU resulted in
almost unchanged plasma phenylalanine concentrations
(Fig. 1B). After 2 weeks of twice daily sublingual BH4
administration, the patient complained of a painful
prickling sensation at the tip of the tongue. He never-
theless continued the treatment for a further 10 days,
moving the tablets in his mouth from one side to the
other, which resulted in severe mucitis. His condition
normalised rapidly upon discontinuation of the sub-
lingual form. No mucitis appeared in healthy volun-
teers.
A clinical trial with sublingual BH4 in a patient with
mild PKU failed despite pharmacological eﬀectiveness
on blood phenylalanine levels because of an adverse
pastille-related side-eﬀect. Formulation of buﬀered tab-
lets approaching neutral pH and further investigations
on BH4 metabolism and pharmacokinetics are needed.
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Fig. 1 A Comparison of total
plasma biopterin levels (median
± SD) after oral or sublingual
administration of BH4 (2 mg/
kg) in four healthy volunteers at
diﬀerent time points. B Dried
blood spot phenylalanine ( solid
squares) and biopterin ( open
squares) measured 3 h after oral
(15 mg/kg) or sublingual
(12 mg/kg) administration of
BH4 in a patient with mild PKU
( s.l.sublingual)
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